Targeted Molecular Treatments in Non-Small Cell Lung Cancer: A Clinical Guide for Oncologists

被引：24
|
作者：
Bui, Kim Tam [1 ]
Cooper, Wendy A. [2 ,3 ,4 ]
Kao, Steven [1 ,4 ]
Boyer, Michael [1 ,4 ]
机构：
[1] Chris OBrien Lifehouse, 119-143 Missenden Rd Camperdown, Camperdown, NSW 2050, Australia
[2] Univ Sydney, Sydney Med Sch, Sydney, NSW 2006, Australia
[3] Western Sydney Univ, Sch Med, Sydney, NSW 2560, Australia
[4] Royal Prince Alfred Hosp, 50 Missenden Rd Camperdown, Camperdown, NSW 2050, Australia
来源：
JOURNAL OF CLINICAL MEDICINE | 2018年 / 7卷 / 08期
关键词：
personalized therapy; non-small cell; lung cancer; targeted therapy; mutation; rearrangement; RANDOMIZED PHASE-III; PLATINUM-BASED CHEMOTHERAPY; OPEN-LABEL; 1ST-LINE TREATMENT; DOUBLE-BLIND; MAINTENANCE THERAPY; EGFR MUTATIONS; SINGLE-ARM; CARBOPLATIN-PACLITAXEL; ACQUIRED-RESISTANCE;
D O I：
10.3390/jcm7080192
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Targeted molecular treatments have changed the way non-small cell lung cancer (NSCLC) is managed. Epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), v-raf murine sarcoma viral oncogene homolog B1 (BRAF), and c-ros oncogene 1 (ROS1) mutations are now used to guide specific anti-cancer therapies to improve patient outcomes. New targeted molecular treatments are constantly being developed and evaluated as a means to improve efficacy, overcome resistance, or minimise toxicity. This review article summarises the current evidence for the efficacy, resistance mechanisms, and safety of targeted molecular treatments against specific mutations in NSCLC.
引用
收藏
页数：18
相关论文
共 50 条
  • [1] Emerging Targeted Therapies for the Treatment of Non-small Cell Lung Cancer
    Halliday, Patrick R.
    Blakely, Collin M.
    Bivona, Trever G.
    CURRENT ONCOLOGY REPORTS, 2019, 21 (03)
  • [2] Targeted treatment of non-small cell lung cancer
    Scheffler, Matthias
    Michels, Sebastian
    Nogova, Lucia
    INNERE MEDIZIN, 2022, 63 (07): : 700 - 708
  • [3] Emerging targeted therapies in non-small cell lung cancer
    Khanal, Nabin
    Ganti, Apar Kishor
    EXPERT REVIEW OF ANTICANCER THERAPY, 2016, 16 (02) : 177 - 187
  • [4] Targeted therapies in non-small cell lung cancer in 2014
    Leduc, C.
    Besse, B.
    REVUE DES MALADIES RESPIRATOIRES, 2015, 32 (02) : 182 - 192
  • [5] Targeted Therapy for Non-Small Cell Lung Cancer
    Jett, James R.
    Carr, Laurie L.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2013, 188 (08) : 907 - 912
  • [6] Targeted therapies for non-small cell lung cancer
    Dempke, Wolfram C. M.
    Suto, Tamas
    Reck, Martin
    LUNG CANCER, 2010, 67 (03) : 257 - 274
  • [7] Immunotherapy in the landscape of new targeted treatments for non-small cell lung cancer
    Gerard, Catherine
    Debruyne, Channa
    MOLECULAR ONCOLOGY, 2009, 3 (5-6) : 409 - 424
  • [8] Precision Management of Advanced Non-Small Cell Lung Cancer
    Yang, Ching-Yao
    Yang, James Chih-Hsin
    Yang, Pan-Chyr
    ANNUAL REVIEW OF MEDICINE, VOL 71, 2020, 2020, 71 : 117 - 136
  • [9] Novel targeted therapies for advanced non-small lung cancer
    Abughanimeh, Omar
    Kaur, Anahat
    El Osta, Badi
    Ganti, Apar Kishor
    SEMINARS IN ONCOLOGY, 2022, 49 (3-4) : 326 - 336
  • [10] Molecular treatment stratification of non-small cell lung cancer
    Lang, Susanne M.
    Rachow, Tobias
    ONKOLOGE, 2020, 26 (08): : 727 - 735
12345